Publication at Faculty of Medicine in Hradec Králové |
2022
Abstract
Secondary-progressive multiple sclerosis is the second most common form of multiple sclerosis. However, diagnosis of secondary-progressive multiple sclerosis is often established retropspectively and delayed up to three years due to several patient factors and clinician-related factors.
Siponimod is the first oral drug to treat secondary-progressive multiple sclerosis, that showed a statistically significant decrease in disabilitiy progression. A case study describes almost 22-year period of man treated with multiple sclerosis.